Nafithromycin: advancements in antibiotic therapy against community-acquired pneumonia-resistant pathogens
Nafithromycin (WCK 4873) is a novel lactone ketolide antibiotic developed to address the critical issue of multidrug-resistant bacteria, especially those causing community-acquired pneumonia (CAP). Given the increasing prevalence of antibiotic resistance, there is a pressing need for new antibiotic...
Saved in:
| Main Authors: | Akshata Gore, Agadi Hiremath Viswanatha Swamy, Sanatkumar Bharamu Nyamagoud |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2025-08-01
|
| Series: | Monaldi Archives for Chest Disease |
| Subjects: | |
| Online Access: | https://www.monaldi-archives.org/macd/article/view/3340 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novelties in the treatment of community-acquired and hospital-acquired pneumonia
by: Matteo Bassetti, et al.
Published: (2025-04-01) -
The Risk Factors of Multidrug-Resistant Organisms in Hospitalized Patients with Community-Acquired Pneumonia in Dr. Soetomo Hospital Surabaya, Indonesia
by: Soedarsono Soedarsono, et al.
Published: (2021-07-01) -
Hospital-acquired pneumonia: risk factors and prognosis, microbial etiology, treatment, and prophylaxis
by: Davide Calabretta, et al.
Published: (2025-04-01) -
Antibiotic Therapy of Severe Community-Acquired Pneumonia
by: O. V. Molchanova, et al.
Published: (2020-05-01) -
Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency
by: Xu J, et al.
Published: (2024-11-01)